Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 15, 2025Frontiers in ImmunologyOpen Access

Post-transplant cyclophosphamide in haploidentical stem cell transplantation: evaluating the impact of transplant conditioning intensity

View Full Paper
Ask AI
Bookmark
Share

Authors

UPUmberto PizzanoSPSimona PiemonteseGFGabriele Facchin

Discussion

Loading...

Member takes

Overview

Observational analysis reveals the impact of transplant conditioning intensity on GvHD outcomes in haplo-HCT, suggesting strategies for better management.

Key Points

  • Higher incidence of chronic graft-versus-host disease occurs with sirolimus-MMF plus posttransplant cyclophosphamide, indicating a need for careful regimen choice.
  • Stratification by conditioning intensity shows that high TCI is the only risk factor for increased grades III–IV acute graft-versus-host disease.
  • Data collected from 216 haplo-HCTs demonstrates overlapping survival outcomes despite differences in conditioning regimens.
  • Results highlight the need for optimized prophylactic strategies to address the quality of life impacted by severe chronic graft-versus-host disease.

Cite This Study

Pizzano et al. (2025) studied this question.

synapsesocial.com/papers/68af50a7ad7bf08b1ead8dcahttps://doi.org/10.3389/fimmu.2025.1610391
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Severity and organ distribution of graft‐versus‐host disease with post‐transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA‐matched or single‐allele mismatched stem cell transplantation2024 · 5 citations
  2. 2Post‐transplantation cyclophosphamide versus conventional graft‐versus‐host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation2016 · 85 citations
  3. 3Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study2025
  4. 4Safety and efficacy of post transplant cyclophosphamide vs tacrolimus plus methotrexate for gvhd prophylaxis in myelofibrosis2025
  5. 5Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients with acute myeloid leukemia and myelodysplastic syndromes: A study from the french society of bone marrow transplantation (SFGM-TC) registry2025